PATENT CLAIM ANALYSIS

Application Number: 16118535
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-01
Patent Classification: ["424", "443000"]

Abstract:
A pharmaceutical composition for administration of Dabigatran zetexilate through the mucous membranes of the oral cavity, characterized in that the composition comprises a therapeutically effective amount of Dabigatran etexilate and a solubilizer for Dabigatran etixilate selected from at least one of a water soluble derivative of tocopherol and a polymeric derivative of sorbitan. The composition may be in the form of solid oral film. The composition may be suitable for dropwise administration. A method of manufacturing the film composition is also included.

Claim (Index 7):
The composition according to  claim 1 , wherein the water soluble cellulose is hydroxypropyl methylcellulose (HPMC).

Metadata:
- Claim Count in Document: 5.0
- Percentile: 96.0
- Lexical Diversity: 1.67308
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15185888', '13636310', '14714195', '14080505', '15308014']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7477959999342865
- 35 USC 102 Novelty (BERT): 0.5098672071986068
- Combined Prediction Score: 0.7240031206607185
- Mean Citation Score: 243.38857400000003
- Max Citation Score: 260.60684
- Similarity Product: 171.53076081345318

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test